ViTToria Biotherapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

ViTToria Biotherapeutics is a private, clinical-stage biotech founded in 2021, advancing a novel CAR T-cell therapy platform called Senza5. The company's lead program, VIPER-101, is in a Phase 1 trial for T-cell lymphoma, representing a move beyond the B-cell cancers addressed by current approved CAR-Ts. ViTToria's technology aims to overcome key limitations of existing cell therapies—including relapse, toxicity, and manufacturing complexity—by modulating CD5 signaling and utilizing a rapid 5-day manufacturing process. The leadership team combines deep expertise in immunology, drug development, and company building.

OncologyImmunology

Technology Platform

Senza5™ platform for next-generation, enabled-autologous CAR T-cell therapies. It combines CD5 signaling modulation to enhance T-cell potency and fitness with a novel 5-day manufacturing process aimed at improving efficacy, safety, and accessibility.

Opportunities

The primary opportunity is to expand CAR T-cell therapy beyond the current limitation to B-cell cancers, which represent less than 5% of cancer types, into T-cell malignancies, solid tumors, and autoimmune diseases.

Additionally, the rapid 5-day manufacturing process could significantly reduce cost and improve patient access, providing a competitive advantage in both new and existing markets.

Risk Factors

Key risks include clinical failure of the novel Senza5 platform in ongoing Phase 1 trials, high burn rate and dependence on future fundraising in a challenging capital environment, and intense competition from numerous other companies developing next-generation cell therapies.

The complex biology of targeting T-cell cancers also presents significant technical and safety risks.

Competitive Landscape

ViTToria competes in the crowded and rapidly evolving next-generation CAR T space, facing competition from both large biopharma companies and numerous agile biotechs. Competitors are exploring various strategies including allogeneic (off-the-shelf) CAR-Ts, dual-targeting constructs, and armored CARs. ViTToria's differentiation hinges on its specific CD5 modulation and ultra-fast autologous manufacturing process.

More companies in Cell & Gene Therapy →More companies in United States →